Log in to save to my catalogue

Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy

Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_bdd41061df664c3ba88533a3b50f245e

Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy

About this item

Full title

Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2023-08, Vol.14 (1), p.4771-14, Article 4771

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Despite significant advances in immune checkpoint blockade (ICB), immunosuppression mediated by tumor-associated myeloid cells (TAMCs) poses a major barrier to cancer immunotherapy. In addition, while immunogenic cell death (ICD) provides a viable approach to inducing anti-tumor immune response, it remains unknown how to effectively trigger ICD whi...

Alternative Titles

Full title

Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_bdd41061df664c3ba88533a3b50f245e

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_bdd41061df664c3ba88533a3b50f245e

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-023-40270-5

How to access this item